Champions Oncology, Inc. (CSBR) stock
CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026Score 10/30227% above fair value
$4.44−0.15 (-3.30%)
Close on Nov 18, 2026Market cap $61.80MP/E –Yield –
Champions Oncology free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Champions Oncology's free cash flow for the twelve months ending Jul 31, 2026 was -$6.14M, down 184.8% year over year. For fiscal 2026 it was -$5.04M, down 172.0% from the year before. The highest annual figure on record is $7.00M in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Apr 30, 2026 | -$5.04M | -172.0% |
| FY2025 | Apr 30, 2025 | $7.00M | – |
| FY2024 | Apr 30, 2024 | -$6.97M | -733.9% |
| FY2023 | Apr 30, 2023 | $1.10M | -73.3% |
| FY2022 | Apr 30, 2022 | $4.11M | – |
| FY2021 | Apr 30, 2021 | -$4.96M | -824.4% |
| FY2020 | Apr 30, 2020 | $685.00K | -33.4% |
| FY2019 | Apr 30, 2019 | $1.03M | – |
| FY2018 | Apr 30, 2018 | -$2.46M | – |
| FY2017 | Apr 30, 2017 | -$3.61M | – |
| FY2016 | Apr 30, 2016 | -$6.73M | – |
| FY2015 | Apr 30, 2015 | -$9.75M | – |
| FY2014 | Apr 30, 2014 | -$3.67M | – |
| FY2013 | Apr 30, 2013 | -$4.36M | – |
| FY2012 | Apr 30, 2012 | -$5.75M | – |
| FY2011 | Apr 30, 2011 | -$139.00K | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jul 31, 2026 | -$547.00K | -198.7% |
| Q4 FY2026CQ1 2026 | Apr 30, 2026 | -$2.24M | -133.8% |
| Q3 FY2026CQ4 2025 | Jan 31, 2026 | -$1.38M | -407.1% |
| Q2 FY2026CQ3 2025 | Oct 31, 2025 | -$1.98M | – |
| Q1 FY2026CQ2 2025 | Jul 31, 2025 | $554.00K | +78.1% |
| Q4 FY2025CQ1 2025 | Apr 30, 2025 | $6.62M | – |
| Q3 FY2025CQ4 2024 | Jan 31, 2025 | $448.00K | – |
| Q2 FY2025CQ3 2024 | Oct 31, 2024 | -$377.00K | -173.9% |
| Q1 FY2025CQ2 2024 | Jul 31, 2024 | $311.00K | – |
| Q4 FY2024CQ1 2024 | Apr 30, 2024 | -$1.81M | – |
| Q3 FY2024CQ4 2023 | Jan 31, 2024 | -$1.01M | -223.4% |
| Q2 FY2024CQ3 2023 | Oct 31, 2023 | $510.00K | -81.0% |
| Q1 FY2024CQ2 2023 | Jul 31, 2023 | -$4.66M | – |
| Q4 FY2023CQ1 2023 | Apr 30, 2023 | -$1.45M | -600.7% |
| Q3 FY2023CQ4 2022 | Jan 31, 2023 | $819.00K | -78.7% |
| Q2 FY2023CQ3 2022 | Oct 31, 2022 | $2.68M | +305.1% |
| Q1 FY2023CQ2 2022 | Jul 31, 2022 | -$949.00K | – |
| Q4 FY2022CQ1 2022 | Apr 30, 2022 | $290.00K | – |
| Q3 FY2022CQ4 2021 | Jan 31, 2022 | $3.85M | – |
| Q2 FY2022CQ3 2021 | Oct 31, 2021 | $662.00K | +77.5% |
| Q1 FY2022CQ2 2021 | Jul 31, 2021 | -$691.00K | – |
| Q4 FY2021CQ1 2021 | Apr 30, 2021 | -$2.83M | -378.4% |
| Q3 FY2021CQ4 2020 | Jan 31, 2021 | -$1.07M | -1088.9% |
| Q2 FY2021CQ3 2020 | Oct 31, 2020 | $373.00K | -36.5% |
| Q1 FY2021CQ2 2020 | Jul 31, 2020 | -$1.43M | – |
| Q4 FY2020CQ1 2020 | Apr 30, 2020 | $1.02M | +817.1% |
| Q3 FY2020CQ4 2019 | Jan 31, 2020 | $108.00K | -89.2% |
| Q2 FY2020CQ3 2019 | Oct 31, 2019 | $587.00K | – |
| Q1 FY2020CQ2 2019 | Jul 31, 2019 | -$1.03M | -922.4% |
| Q4 FY2019CQ1 2019 | Apr 30, 2019 | $111.00K | – |
| Q3 FY2019CQ4 2018 | Jan 31, 2019 | $1.00M | +171.1% |
| Q2 FY2019CQ3 2018 | Oct 31, 2018 | -$211.00K | -189.4% |
| Q1 FY2019CQ2 2018 | Jul 31, 2018 | $125.00K | – |
| Q4 FY2018CQ1 2018 | Apr 30, 2018 | -$203.00K | – |
| Q3 FY2018CQ4 2017 | Jan 31, 2018 | $370.00K | – |
| Q2 FY2018CQ3 2017 | Oct 31, 2017 | $236.00K | +129.1% |
| Q1 FY2018CQ2 2017 | Jul 31, 2017 | -$2.86M | – |
| Q4 FY2017CQ1 2017 | Apr 30, 2017 | -$187.00K | – |
| Q3 FY2017CQ4 2016 | Jan 31, 2017 | -$835.00K | – |
| Q2 FY2017CQ3 2016 | Oct 31, 2016 | $103.00K | – |
See a number that looks wrong?